After counterfeit Avastin® - What have we learned and what can be done?

Nature Reviews Clinical Oncology

Volumn 12, Issue 5, 2015, Pages 302-308

  Mackey, Tim K ^a   Cuomo, Raphael ^b,c   Guerra, Camille ^c,d   Liang, Bryan A ^e  

^a Department of Neurology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d SAN DIEGO STATE UNIVERSITY   (United States)

^e CALIFORNIA WESTERN SCHOOL OF LAW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; COUNTERFEIT DRUG;

COST EFFECTIVENESS ANALYSIS; COURT; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; LAW; LEGAL ASPECT; MALIGNANT NEOPLASTIC DISEASE; PATIENT SAFETY; POLICY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; UNITED STATES; CRIME; DRUG CONTROL; LEGISLATION AND JURISPRUDENCE; STANDARDS; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; COUNTERFEIT DRUGS; CRIME; DRUG AND NARCOTIC CONTROL; HUMANS; PATIENT SAFETY; UNITED STATES;

EID: 84928829480     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.35     Document Type: Review

References (69)

1. US Food and Drug Administration. Counterfeit Version of Avastin in U. S. Distribution [online], http://www.fda.gov/drugs/drugsafety/ucm291960.htm (2012).
2. PMGroup, PMLiVE. Top 50 pharmaceutical products by global sales [online], http://www.pmlive.com/top-pharma-list/Top-50-pharmaceutical-products-by-global-sales (2015).
3. Weaver, C. & Whalen, J. How Fake Cancer Drugs Entered U. S. The Wall Street Journal [online], http://online.wsj.com/news/articles/SB10001424052702303879604577410430607090226 (2012).
4. Attaran, A. et al. How to achieve international action on falsified and substandard medicines. BMJ 345, e7381 (2012).
5. Mackey, T. K. & Liang, B. A. Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Med. 11, 233 (2013).
6. Mackey, T. K. & Liang, B. A. Oncology and the Internet: regulatory failure and reform. J. Oncol. Pract. 8, 341-343 (2012).
7. Institute for Safe Medication Practices. Gray Market, Black Heart: Pharmaceutical Gray Market Finds a Disturbing Niche During the Drug Shortage Crisis [online], http://www.ismp.org/Newsletters/acutecare/showarticle.asp?ID=3 (2011).
8. Whalen, J. Egypt Eyed as Possible Source of Fake Avastin. The Wall Street Journal [online], http://online.wsj.com/articles/SB10001424052970204880404577229380581802606 (2012).
9. Sandle, P. & Acher, J. Denmark's CareMed says shipped fake Avastin unwittingly. Reuters [online], http://www.reuters.com/article/2012/02/17/us-caremed-Avastin-idUSTRE81G1S920120217 (2012).
10. US Food and Drug Administration. Letters to Doctors about Risks of Purchasing Medications from Foreign or Unlicensed Suppliers [online], http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/ucm330610.htm (2012).
11. Weaver, C., Whalen, J. & Faucon, B. Drug Distributor Is Tied to Imports of Fake Avastin. The Wall Street Journal [online], http://www.wsj.com/articles/SB10001424052970203370604577261343974214110 (2012).
12. Kuehn, B. M. FDA warning: new batch of fake bevacizumab found. JAMA 309, 864-864 (2013).
13. US Food and Drug Administration. August 23, 2012: California Man Sentenced for Importing Adulterated Cancer Drugs; Forfeits $1.4 Million & Land Rover Automobile [online], http://www.fda.gov/ICECI/CriminalInvestigations/ucm316986.htm (2012).
14. US Food and Drug Administration. July 11, 2013: English Citizen Sentenced for Distributing Adulterated and Counterfeit Cancer Drugs [online], http://www.fda.gov/ICECI/CriminalInvestigations/ucm360652.htm (2013).
15. Department of Justice. United States Attorney's Office, Eastern District of Tennessee. Greeneville Oncologist And Practice Manager Sentenced For Violating Food, Drug And Cosmetic Act: Cancer Clinic Purchased Unapproved Drugs for Three Years [online], http://www.justice.gov/usao/tne/news/2014/June/061214%20Sen%20Sentencing%20FDA.html (2014).
16. The Federal Bureau of Investigation, Knoxville Division. Johnson City Physician Sentenced to Serve Two Years in Prison for Violations Related to Unapproved Foreign Drugs [online], http://www.fbi.gov/knoxville/press-releases/2013/johnson-city-physician-sentenced-To-serve-Two-years-in-prison-for-violations-related-To-unapproved-foreign-drugs (2013).
17. Weaver, C. U. S. Fake-Drug Probe Puts Spotlight on Role of Doctors. The Wall Street Journal [online], http://online.wsj.com/news/articles/SB10001424127887323353204578129682462065220 (2012).
18. US Food and Drug Administration. January 16, 2014: Two Turkish Nationals Indicted for Smuggling Counterfeit Cancer Drug [online], http://www.fda.gov/ICECI/CriminalInvestigations/ucm383001.htm (2014).
19. Whalen, J. Turkish Drug Exporter Ozay Draws U. S. Scrutiny. The Wall Street Journal [online], http://online.wsj.com/news/articles/SB10001424052702303546204579435692215579758 (2014).
20. Department of Justice. United States Attorney's Office, Eastern District of New York. Two Officers Of Long Island Based Company Indicted For Sale.Of $17 Million Worth Of Misbranded Prescription Drugs Including Counterfeit Cancer Drugs [online], http://www.justice.gov/usao/nye/pr/April14/2014Apr30.php (2014).
21. US Food and Drug Administration. February 16, 2012: Local Cancer Doctor Pleads Guilty to Receiving Misbranded Cancer Drugs Two Californians also Named in Indictment [online], http://www.fda.gov/ICECI/CriminalInvestigations/ucm294706.htm (2012).
22. Liang, B. A. & Mackey, T. Searching for safety: addressing search engine, website, and provider accountability for illicit online drug sales. Am. J. Law Med. 35, 125-184 (2009).
23. Institute of Medicine. Countering the Problem of Falsified and Substandard Drugs [online], http://www.iom.edu/Reports/2013/Countering-The-Problem-of-Falsified-And-Substandard-Drugs.aspx (2013).
24. Qureshi, Z. P. et al. Caveat Oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States. J. Oncol. Pract. 8, 84-90 (2012).
25. Sun, X., Xu, X. & Zhang, X. Counterfeit bevacizumab and endophthalmitis. N. Engl. J. Med. 365, 378-379 (2011).
26. Garcia-Aguirre, G., Vanzinni-Zago, V. & Quiroz-Mercado, H. Growth of Scytalidium sp. in a counterfeit bevacizumab bottle. Indian J. Ophthalmol. 61, 523-525 (2013).
27. Wang, F. et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology 120, 355-361 (2013).
28. Mackey, T. K. & Liang, B. A. The global counterfeit drug trade: patient safety and public health risks. J. Pharm. Sci. 100, 4571-4579 (2011).
29. Almuzaini, T., Sammons, H. & Choonara, I. Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011). BMJ Open 3, e002924 (2013).
30. Gostin, L. O., Buckley, G. J. & Kelley, P. W. Stemming the global trade in falsified and substandard medicines. JAMA 309, 1693-1694 (2013).
31. Karunamoorthi, K. The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence. Malar. J. 13, 209 (2014).
32. Newton, P. N., Green, M. D. & Fernández, F. M. Impact of poor-quality medicines in the 'developing' world. Trends Pharmacol. Sci. 31, 99-101 (2010).
33. Nayyar, G. M., Breman, J. G., Newton, P. N. & Herrington, J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect. Dis. 12, 488-496 (2012).
34. Mackey, T. K. Global health diplomacy and the governance of counterfeit medicines: a mapping exercise of institutional approaches. Journal of Health Diplomacy [online], http://www.ghd-net.org/sites/default/files/Global%20Health%20Diplomacy%20and%20the%20Governance%20of%20Counterfeit%20Medicines.pdf (2013).
35. Rosenthal, E. T. The 'gray market' raises concerns about cost, safety, and ethics. J. Natl Cancer Inst. 104, 168-170 (2012).
36. Woodward, C. Prices gone wild: grey market 'scalpers' scoring windfall in American drug market. CMAJ 184, E119-E120 (2012).
37. Forman, R. F. Availability of opioids on the Internet. JAMA 290, 889 (2003).
38. Liang, B. A. & Mackey, T. K. Online availability and safety of drugs in shortage: a descriptive study of internet vendor characteristics. J. Med. Internet Res. 14, e27 (2012).
39. Liang, B. A. & Mackey, T. K. Vaccine shortages and suspect online pharmacy sellers. Vaccine 30, 105-108 (2012).
40. Mackey, T. K., Liang, B. A. & Strathdee, S. A. Digital social media, youth, and nonmedical use of prescription drugs: the need for reform. J. Med. Internet Res. 15, e143 (2013).
41. Orizio, G. et al. 'Save 30% if you buy today'. Online pharmacies and the enhancement of peripheral thinking in consumers. Pharmacoepidemiol. Drug Saf. 19, 970-976 (2010).
42. CBC News. Canadadrugs.com's wholesale licence suspended [online], http://www.cbc.ca/1.2669583 (2014).
43. Mackey, T. K. & Liang, B. A. Pharmaceutical digital marketing and governance: illicit actors and challenges to global patient safety and public health. Global Health 9, 45 (2013).
44. Brookings Institute. Reducing the Threat of Counterfeit and Unapproved Drugs in Clinical Settings [online], http://www.brookings.edu/events/2013/07/19-counterfeit-unapproved-drugs-Threat (2013).
45. Crino, L. et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 11, 733-740 (2010).
46. Hurwitz, H. & Saini, S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin. Oncol. 33, S26-S34 (2006).
47. Saif, M. W. Managing bevacizumab-related toxicities in patients with colorectal cancer. J. Support. Oncol. 7, 245-251 (2009).
48. Hershman, D. L. et al. Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. J. Clin. Oncol. 31, 3592-3599 (2013).
49. Moisee, K. Cancer Patients Furious Over Counterfeit Avastin. ABC News [online], http://abcnews.go.com/Health/CancerPreventionAndTreatment/cancer-patients-furious-counterfeit-Avastin/story?id=15629540 (2012).
50. US Food and Drug Administration. Drug Supply Chain Security Act (DSCSA) [online], http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/DrugSupplyChainSecurityAct/(2013).
51. Outterson, K. The Drug Quality and Security Act-mind the gaps. N. Engl. J. Med. 370, 97-99 (2014).
52. US Food and Drug Administration. Guidance for Industry: Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification [online], http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM400470.pdf (2014).
53. Bansal, D., Malla, S., Gudala, K. & Tiwari, P. Anti-counterfeit technologies: a pharmaceutical industry perspective. Sci. Pharm. 81, 1-13 (2013).
54. Yukhananov, A. Congress fails to agree on national drug trace plan. Reuters [online], http://www.reuters.com/article/2012/06/18/us-congress-fda-Trace-idUSBRE85H1QF20120618 (2012).
55. Barlas, S. Track-And-Trace drug verification: FDA plans new national standards, pharmacies tread with trepidation. PT 36, 203-231 (2011).
56. Mackey, T. K. & Liang, B. A. Combating healthcare corruption and fraud with improved global health governance. BMC Int. Health Hum. Rights 12, 23 (2012).
57. Yip, W. & Mahal, A. The health care systems of China and India: performance and future challenges. Health Affairs 27, 921-932 (2008).
58. Gautam, C. S., Utreja, A. & Singal, G. L. Spurious and counterfeit drugs: a growing industry in the developing world. Postgrad. Med. J. 85, 251-256 (2009).
59. Congressman Patrick Meehan, Representing the 7th District of Pennsylvania. Meehan Bill to Crackdown on Counterfeit Rx Drug Trafficking Passes House [online], http://meehan.house.gov/latest-news/meehan-bill-To-crackdown-on-counterfeit-rx-drug-Trafficking-passes-house/(2012).
60. [No authors listed] Shortages of cancer drugs in the USA. Lancet Oncol. 12, 313 (2011).
61. Gatesman, M. L. & Smith, T. J. The shortage of essential chemotherapy drugs in the United States. N. Engl. J. Med. 365, 1653-1655 (2011).
62. Montero, A. J. & Vogel, C. Fighting fire with fire: rekindling the bevacizumab debate. N. Engl. J. Med. 366, 374-375 (2012).
63. Kolata, G. & Pollack, A. The Evidence Gap: Costly Cancer Drug Offers Hope, but Also a Dilemma. The New York Times [online], http://www.nytimes.com/2008/07/06/health/06avastin.html?pagewanted=all&-r=0 (2008).
64. Jirillo, A., Vascon, F. & Giacobbo, M. Bevacizumab in advanced cancer, too much or too little? Ann. Oncol. 19, 1817-1818 (2008).
65. Berkrot, B. Roche's Genentech defends supply shift for top cancer drugs. Yahoo Finance [online], http://finance.yahoo.com/news/roches-genentech-defends-supply-shift-233532371.html (2014).
66. Kelly, R. J. & Smith, T. J. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 15, e112-e118 (2014).
67. Mileshkin, L. & Sullivan, D. Access to expensive anti-cancer drugs. J. Law Med. 19, 232-243 (2011).
68. Essential Medicines and Health Products Information Portal. Promoting Access to Medical Technologies and Innovation. Intersections Between Public Health, Intellectual Property and Trade [online], http://apps.who.int/medicinedocs/en/d/Js20030en/(2013).
69. Mackey, T. K. & Liang, B. A. Promoting global health: utilizing WHO to integrate public health, innovation and intellectual property. Drug Discov. Today 17, 1254-1257 (2012).